Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 7/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587382 | 0.98 | SLC15A2 (0.41) | SLC15A2GHSRMMP1OPRK1OPRM1 | |
| SCHEMBL2242457 | 0.94 | SLC15A2 (0.41) | SLC15A2GHSRMMP1OPRK1OPRM1 | |
| SCHEMBL4588264 | 0.92 | SLC15A2 (0.41) | SLC15A2GHSRMMP1OPRK1OPRM1 | |
| SCHEMBL2247601 | 0.92 | SLC15A2 (0.42) | SLC15A2GHSRMMP1ERAP2ERAP1 | |
| SCHEMBL5969687 | 0.92 | PLG (0.40) | SLC15A2GHSRMMP1OPRK1OPRM1 | |
| SCHEMBL4588260 | 0.90 | SLC15A2 (0.42) | SLC15A2GHSRMMP1ERAP2ERAP1 | |
| SCHEMBL4589867 | 0.90 | PLG (0.40) | SLC15A2GHSRMMP1OPRK1OPRM1 | |
| SCHEMBL2815939 | 0.89 | SLC15A2 (0.39) | SLC15A2GHSROPRK1ERAP2ERAP1 | |
| SCHEMBL2813367 | 0.87 | SLC15A2 (0.41) | SLC15A2GHSROPRK1 | |
| SCHEMBL2815083 | 0.87 | SLC15A2 (0.54) | SLC15A2GHSRMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2005-11-24 | — | — | US | claimed |
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, TFRC | SLC15A2 1553/4885GHSR 854/4885MMP1 2394/4885 |
| US-20050260275-A1 | Encapsulated peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, CTRC | SLC15A2 981/4885GHSR 1411/4885MMP1 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.